Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Other Income/Expenses (Net) Over TimeExpanding
Percentile Rank100
3Y CAGR+303.0%
5Y CAGR+147.3%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

3Y CAGR
+303.0%/yr
vs -7.1%/yr prior
5Y CAGR
+147.3%/yr
Recent acceleration
Acceleration
+310.2pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
92.4x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$54.34M+8972.5%
2024$599000.00+100.6%
2023$-96.51M-11728.1%
2022$830000.00+7645.5%
2021$-11000.00-101.9%
2020$588000.00-71.7%
2019$2.08M+86.5%
2018$1.11M+153.4%
2017$440000.00+111.5%
2016$208000.00-